Reliant AI, a provider of gen AI-powered data analytics software, announced its launch out of stealth with $11.3 million in seed funding. The new capital was co-led by Tola Capital and Inovia Capital, with participation from angel investor Mike Volpi.
GenAI Analytics Provider, Reliant AI, Launches Out of Stealth with $11.3M In Seed Funding
August 26, 2024 by
Pharmaceutical Supply Chain Data is in the Dark Ages: It’s Time to Bring it into the Future
February 16, 2023 by
In this contributed article, Nico Ros, Co-founder and CTO of SkyCell, discusses how the industry is crying out for better logistical solutions and needs for better remote monitoring. Disparate data solutions are just not up to the mark anymore – but there is an answer to this problem. Combining simulation data and operational data (SO data) can bridge this visibility gap.
Pumas-AI Launches Julia Language-Based Software to Advance Drug Development, Patient Care
August 4, 2019 by
Pumas-AI – a new company established by University of Maryland School of Pharmacy faculty members Vijay Ivaturi, PhD, assistant professor in the Department of Pharmacy Practice and Science (PPS), and Joga Gobburu, PhD, MBA, professor in PPS – is proud to announce the release of its first cutting-edge software platform for pharmaceutical researchers and clinicians. Known as Pharmaceutical Modeling and Simulation (Pumas), the software was developed through a partnership with experts at Julia Computing.
Data Systems Strategies for Today’s Challenges
May 3, 2017 by
To address today’s challenges and come up with viable data systems strategies, pharmaceutical companies are looking outside the industry to leverage scientific and technical innovation in other markets.
Global CEO Initiative on Alzheimer’s Disease Announces a Big Data Challenge
November 11, 2013 by
Challenge to be first in a series to crowdsource Alzheimer’s data for new disease insights .
Leveraging High Quality Data to Discover Drugs
November 7, 2013 by
The IP & Science Business of Thomson Reuters has announced a strategic initiative with NuMedii. The companies will leverage high-quality data, knowledge and predictive technologies to identify therapeutic candidates with the greatest probability for clinical success.
